Baxter International Inc. (BAX): A Bull Case Theory

We came across a bullish thesis connected Baxter International Inc. connected Value investing subreddit by Mr-Gambini. In this article, we volition summarize the bulls’ thesis connected BAX. Baxter International Inc.'s stock was trading astatine $19.29 arsenic of December 17th. BAX’s guardant P/E was 8.12 according to Yahoo Finance.

Copyright: nimon / 123RF Stock Photo

Baxter International (BAX) is simply a quintessential “boring but essential” medtech company operating in oligopolistic markets for IV solutions, infusion pumps, diligent monitoring, and infirmary equipment, wherever request is non-discretionary and lawsuit relationships are profoundly entrenched. The banal has been driven to multi-decade lows adjacent $19 pursuing a bid of setbacks, but the caller selloff reflects highest capitulation alternatively than structural deterioration.

Under caller CEO Andrew Hider, Baxter delivered a textbook “kitchen sink” 4th successful Q3, resetting expectations aggressively by cutting guidance, slashing the dividend to sphere implicit $300 cardinal successful yearly currency for deleveraging, and acknowledging slower-than-expected recoveries successful IV fluids and the paused Novum IQ infusion pump. While reported income missed lowered expectations and full-year maturation was revised to 1–2%, margins continued to improve, escaped currency travel turned positive, and operating subject intensified, with SG&A reductions and operating margins expanding meaningfully twelvemonth implicit year.

Importantly, the issues weighing connected sentiment are impermanent and fixable: the Novum IQ pump had been gaining marketplace stock rapidly earlier its voluntary hold, bequest alternatives are ramping well, and IV fluid accumulation is afloat restored adjacent arsenic infirmary normalization lags, a signifier accordant with past disruptions. Capital spending request from hospitals remains strong, tariffs are manageable, and deleveraging is firmly connected track.

With Hider bringing Danaher-style operational rigor and a proven turnaround track record, Baxter is positioning itself arsenic a self-help communicative heading into a 2026 capitalist reset. At roughly 9–10x forward earnings amid washed-out healthcare sentiment, the banal offers an asymmetric risk-reward, wherever impermanent sound is being mispriced arsenic imperishable impairment.

Previously we covered a bullish thesis on Medtronic plc (MDT) by Magnus Ofstad successful May 2025, which highlighted the company’s strategical transformation, activistic involvement, and worth unlocking done divestitures and innovation. The company's banal terms has appreciated approximately by 21.83% since our coverage. This is due to the fact that the thesis played retired partially. The thesis inactive stands arsenic execution remains ongoing. Mr-Gambini shares a akin thesis but emphasizes connected self-help turnaround and equilibrium expanse repair.